PMA supplement
BP050009 S001: Chembio HIV Reactive/Nonreactive Controls; Clearview Complete HIV 1/2
FDA PMA supplement · 30-Day Notice · Chembio Diagnostic Systems, In
Key facts
| Original PMA | BP050009 |
|---|---|
| Supplement number | S001 |
| Supplement type | 30-Day Notice |
| Trade name | Chembio HIV Reactive/Nonreactive Controls; Clearview Complete HIV 1/2 |
| Generic name | Point of care hiv serology diagnostic and/or supplemental test |
| Applicant | Chembio Diagnostic Systems, In |
| Product code | QSU |
| Received date | Jan 16, 2007 |
| Decision date | Feb 9, 2007 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: